Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
AOK PLUS - THE HEALTH INSURANCE COMPANY FOR SAXONY AND THURINGIA has floated a tender for Non-exclusive Drug Discount Agreements in Accordance with Section 130a (8) Sgb V with the Option of Concluding the Active Ingredient Adalimumab at Any Time (atc Codes According to Who: L04ab04). The project location is Germany and the tender is closing on 30 Nov 2021. The tender notice number is 014021-2021, while the TOT Ref Number is 49213337. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : Germany
Summary : Non-exclusive Drug Discount Agreements in Accordance with Section 130a (8) Sgb V with the Option of Concluding the Active Ingredient Adalimumab at Any Time (atc Codes According to Who: L04ab04)
Deadline : 30 Nov 2021
Other Information
Notice Type : Tender
TOT Ref.No.: 49213337
Document Ref. No. : 014021-2021
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : AOK PLUS - THE HEALTH INSURANCE COMPANY FOR SAXONY AND THURINGIA
Address: Augustinerstraße 38
Town: Erfurt
NUTS code: DEG01 - Erfurt, district-free city of
Postal Code: 99084
Contact Point: Corporate Governance Division, Central Registration Office Division, e. H. Attorney Sören Rabe
Germany
Email :vergabestelle@plus.aok.de
URL :https://plus.aok.de
Tender Details
Document Type: Corrigendum / Additional information (Please refer tender document)
Title: Non-exclusive drug discount agreements in accordance with Section 130a, Paragraph 8 of Book V of the Social Code, with the option to take out adalimumab at any time (ATC codes according to WHO: L04AB04)
Reference Number: 147/2020-OH
Contract Type: Supplies
Description: The subject of this publication is the conclusion of non-exclusive discount agreements in accordance with Section 130a (8) SGB V for drugs containing the active ingredient adalimumab (ATC codes according to WHO: L04AB04) within the framework of a so-called “open-house model”. All interested and suitable pharmaceutical companies are offered the conclusion of a discount agreement in accordance with Section 130a (8) SGB V, subject to uniform conditions and a uniform access procedure. There is no exclusivity. The purchase quantity is unknown when the agreement is concluded and depends in particular on the demand from the insured, the development of the number of insured, the prescription behavior of the contract doctors and the dispensing and stocking behavior of the public pharmacies. The client does not guarantee any minimum purchase quantities. b ...
Documents
Want To Bid in This Tender?
Get Local Agent Support in Germany and 60 More Countries.
View Tenders By
Sign in with Google